Slide background
Certifico: Informazione tecnica HSE / 25° anno

/ Documenti disponibili: 43.844
/ Totale documenti scaricati: 31.056.020

Vedi Abbonamenti, Prodotti tecnici e Software 2025

* Dati in real-time da Aprile 2014 alla data odierna.
 
Slide background
Slide background
Certifico 2000/2024: Informazione Utile




/ Documenti disponibili: 43.844 *

/ Totale documenti scaricati: 31.056.020 *

Vedi Abbonamenti, Prodotti e Software 2024


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2024: Informazione Utile

/ Documenti disponibili: 43.844 *

/ Totale documenti scaricati: 31.056.020 *

Vedi Abbonamenti Promo 2023


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Slide background
Certifico 2000/2023: Informazione Utile

/ Documenti disponibili: 43.844 *

/ Totale documenti scaricati: 31.056.020 *


Vedi Abbonamenti Promo 2023


* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2023: Informazione Utile

Slide background
Certifico 2000/2023: Informazione Utile

Slide background
Certifico 2000/2023: Informazione Utile

Abbonamenti Promo fino al 20 Agosto - 20% ticket "CERTIFICO20"

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2023
Slide background
Certifico 2000/2023: Informazione Utile

Abbonamenti Promo fino al 20 Agosto - 20% ticket "CERTIFICO20"

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2023
Slide background
Certifico 2000/2023: Informazione Utile

/ Documenti disponibili: 43.844 *

/ Totale documenti scaricati: 31.056.020 *

Vedi Abbonamenti Promo 2023

* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2022: Informazione Utile

/ Documenti disponibili: 43.844 *

/ Totale documenti scaricati: 31.056.020 *


Vedi Abbonamenti Promo 2022

* Dati in real-time da Aprile 2014 alla data odierna.
Slide background
Certifico 2000/2022: Informazione Utile

Tutti i Software, Prodotti e Documenti Tecnici presenti sono elaborati direttamente

o selezionati su Norme Tecniche & Standards riconosciuti.


Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2022
Slide background
Certifico 2000/2021: Informazione Utile

Tutti i Software, Prodotti e Documenti Tecnici presenti sono elaborati direttamente

o selezionati su Norme Tecniche & Standards riconosciuti.

Vedi Abbonamenti Promo: 2X, 3X, 4X, Full | 2021








Europe, Rome

FDA: Authorization Janssen COVID-19 Vaccine (Johnson & Johnson)

ID 12987 | | Visite: 2206 | NewsPermalink: https://www.certifico.com/id/12987

Temi: Coronavirus

FDA Authorization Janssen COVID 19 Vaccine  Johnson   Johnson

FDA: Authorization Janssen COVID-19 Vaccine (Johnson & Johnson)

February 27, 2021

the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The EUA allows the Janssen COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older.

“The authorization of this vaccine expands the availability of vaccines, the best medical prevention method for COVID-19, to help us in the fight against this pandemic, which has claimed over half a million lives in the United States,” said Acting FDA Commissioner Janet Woodcock, M.D. “The FDA, through our open and transparent scientific review process, has now authorized three COVID-19 vaccines with the urgency called for during this pandemic, using the agency’s rigorous standards for safety, effectiveness and manufacturing quality needed to support emergency use authorization.”

The FDA has determined that the Janssen COVID-19 Vaccine has met the statutory criteria for issuance of an EUA. The totality of the available data provides clear evidence that the Janssen COVID-19 Vaccine may be effective in preventing COVID-19. The data also show that the vaccine’s known and potential benefits outweigh its known and potential risks, supporting the company’s request for the vaccine’s use in people 18 years of age and older. In making this determination, the FDA can assure the public and medical community that it has conducted a thorough evaluation of the available safety, effectiveness and manufacturing quality information.

The Janssen COVID-19 Vaccine is manufactured using a specific type of virus called adenovirus type 26 (Ad26). The vaccine uses Ad26 to deliver a piece of the DNA, or genetic material, that is used to make the distinctive “spike” protein of the SARS-CoV-2 virus. While adenoviruses are a group of viruses that are relatively common, Ad26, which can cause cold symptoms and pink eye, has been modified for the vaccine so that it cannot replicate in the human body to cause illness. After a person receives this vaccine, the body can temporarily make the spike protein, which does not cause disease, but triggers the immune system to learn to react defensively, producing an immune response against SARS-CoV-2.

“After a thorough analysis of the data, the FDA’s scientists and physicians have determined that the vaccine meets the FDA’s expectations for safety and effectiveness appropriate for the authorization of a vaccine for emergency use,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “With today’s authorization, we are adding another vaccine in our medical toolbox to fight this virus. At the same time, the American people can be assured of the FDA’s unwavering commitment to public health through our comprehensive and rigorous evaluation of the data submitted for vaccines to prevent COVID-19.”

FDA Evaluation of Available Safety Data

The Janssen COVID-19 Vaccine is administered as a single dose. The available safety data to support the EUA include an analysis of 43,783 participants enrolled in an ongoing randomized, placebo-controlled study being conducted in South Africa, certain countries in South America, Mexico, and the U.S. The participants, 21,895 of whom received the vaccine and 21,888 of whom received saline placebo, were followed for a median of eight weeks after vaccination. The most commonly reported side effects were pain at the injection site, headache, fatigue, muscle aches and nausea. Most of these side effects were mild to moderate in severity and lasted 1-2 days.

As part of the authorization, the FDA notes that it is mandatory for Janssen Biotech Inc. and vaccination providers to report the following to the Vaccine Adverse Event Reporting System (VAERS) for Janssen COVID-19 Vaccine: serious adverse events, cases of Multisystem Inflammatory Syndrome and cases of COVID-19 that result in hospitalization or death. 

It is also mandatory for vaccination providers to report all vaccine administration errors to VAERS for which they become aware and for Janssen Biotech Inc. to include a summary and analysis of all identified vaccine administration errors in monthly safety reports submitted to the FDA.

FDA Evaluation of Available Effectiveness Data 

The effectiveness data to support the EUA include an analysis of 39,321 participants in the ongoing randomized, placebo-controlled study being conducted in South Africa, certain countries in South America, Mexico, and the U.S. who did not have evidence of SARS-CoV-2 infection prior to receiving the vaccine. Among these participants, 19,630 received the vaccine and 19,691 received saline placebo. Overall, the vaccine was approximately 67% effective in preventing moderate to severe/critical COVID-19 occurring at least 14 days after vaccination and 66% effective in preventing moderate to severe/critical COVID-19 occurring at least 28 days after vaccination. 

Additionally, the vaccine was approximately 77% effective in preventing severe/critical COVID-19 occurring at least 14 days after vaccination and 85% effective in preventing severe/critical COVID-19 occurring at least 28 days after vaccination.

There were 116 cases of COVID-19 in the vaccine group that occurred at least 14 days after vaccination, and 348 cases of COVID-19 in the placebo group during this time period. There were 66 cases of COVID-19 in the vaccine group that occurred at least 28 days after vaccination and 193 cases of COVID-19 in the placebo group during this time period. Starting 14 days after vaccination, there were 14 severe/critical cases in the vaccinated group versus 60 in the placebo group, and starting 28 days after vaccination, there were 5 severe/critical in the vaccine group versus 34 cases in the placebo group. 

At this time, data are not available to determine how long the vaccine will provide protection, nor is there evidence that the vaccine prevents transmission of SARS-CoV-2 from person to person. 

The EUA Process

On the basis of the determination by the Secretary of the Department of Health and Human Services on Feb. 4, 2020, that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and issued declarations that circumstances exist justifying the authorization of emergency use of unapproved products, the FDA may issue an EUA to allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent COVID-19 when there are no adequate, approved, and available alternatives. 

The issuance of an EUA is different than an FDA approval (licensure) of a vaccine, in that a vaccine available under an EUA is not approved. In determining whether to issue an EUA for a product, the FDA evaluates the available evidence to determine whether the product may be effective and also assesses any known or potential risks and any known or potential benefits If the product meets the effectiveness standard and the benefit-risk assessment is favorable, the product is made available during the emergency. Once a manufacturer submits an EUA request for a COVID-19 vaccine to the FDA, the agency then evaluates the request and determines whether the relevant statutory criteria are met, taking into account the totality of the scientific evidence about the vaccine that is available to the FDA.

The EUA also requires that fact sheets that provide important information, including dosing instructions, and information about the benefits and risks of the Janssen COVID-19 Vaccine, be made available to vaccination providers and vaccine recipients.

Janssen Biotech Inc. has submitted a pharmacovigilance plan to the FDA describing its commitment to monitor the safety of Janssen COVID-19 Vaccine. The pharmacovigilance plan includes a plan to complete longer-term safety follow-up for participants enrolled in ongoing clinical trials. The pharmacovigilance plan also includes other activities aimed at monitoring the safety profile of the Janssen COVID-19 Vaccine and ensuring that any safety concerns are identified and evaluated in a timely manner. 

The FDA also expects manufacturers whose COVID-19 vaccines are authorized under an EUA to continue their clinical trials to obtain additional safety and effectiveness information and pursue approval (licensure).

The EUA for the Janssen COVID-19 Vaccine was issued to Janssen Biotech Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. The authorization will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biologics for prevention and treatment of COVID-19 is terminated. The EUA for Janssen COVID-19 Vaccine may be revised or revoked if it is determined the EUA no longer meets the statutory criteria for issuance.

Tags: Coronavirus

Ultimi inseriti

Lug 09, 2025 64

Decreto ministeriale 13 novembre 2024

Decreto ministeriale 13 novembre 2024 ID 24259 | 09.07.2025 Decreto ministeriale 13 novembre 2024Sostegno per l'autoproduzione di energia da fonti rinnovabili nelle PMI Requisiti, modalità di accesso e criteri per la fruizione delle agevolazioni inerenti all’investimento pubblico diretto a… Leggi tutto
Lug 09, 2025 66

Decreto direttoriale 30 giugno 2025

Decreto direttoriale 30 giugno 2025 ID 24258 | 09.07.2025 Decreto direttoriale 30 giugno 2025Autoproduzione di energia da fonti rinnovabili nelle PMI. Riapertura sportello (Comunicato GU n.157 del 09.07.2025) _________ Il decreto fornisce - ai sensi dell’articolo 9 del decreto 13 novembre 2024 - le… Leggi tutto
Decreto 20 maggio 2025
Lug 09, 2025 65

Decreto 20 maggio 2025

Decreto 20 maggio 2025 / Imballaggio medicinali: Disciplina dispositivo ID 24257 | 09.07.2025 Decreto 20 maggio 2025 Disciplina del dispositivo, delle caratteristiche tecniche e grafiche e delle informazioni nel medesimo contenute. (GU n.157 del 09.07.2025) Entrata in vigore: 09.07.2025 _________… Leggi tutto
Decreto Ministeriale n  19 giugno 2025 n  149 Nuovo Decreto agro voltaico
Lug 09, 2025 131

Decreto Ministeriale n. 19 giugno 2025 n. 149

Decreto Ministeriale n. 19 giugno 2025 n. 149 / Nuovo Decreto agro-voltaico ID 24255 | 09.07.2025 / In allegato Con il parere favorevole della Corte dei conti è stato pubblicato il Decreto Ministeriale n. 19 giugno 2025 n. 149 che ha l’obiettivo di facilitare la piena e completa attuazione… Leggi tutto
Patto per l industria pulita
Lug 09, 2025 133

Patto per l'industria pulita

Patto per l'industria pulita ID 24254 | 09.07.2025 La Commissione europea, a febbraio 2025, ha presentato il patto per l'industria pulita, un audace piano operativo volto a sostenere la competitività e la resilienza della nostra industria. Il patto accelererà la decarbonizzazione, garantendo nel… Leggi tutto
Raccomandazione  UE  2025 1307 Incentivi fiscali patto per l industria pulita
Lug 09, 2025 124

Raccomandazione (UE) 2025/1307

in News
Raccomandazione (UE) 2025/1307 / Incentivi fiscali patto per l’industria pulita ID 24253 | 09.07.2025 Raccomandazione (UE) 2025/1307 della Commissione, del 2 luglio 2025, sugli incentivi fiscali a sostegno del patto per l’industria pulita e alla luce della disciplina degli aiuti di Stato… Leggi tutto
Lug 08, 2025 134

Regolamento (UE) n. 913/2010

Regolamento (UE) n. 913/2010 ID 24252 | 08.07.2025 Regolamento (UE) n. 913/2010 del Parlamento europeo e del Consiglio, del 22 settembre 2010, relativo alla rete ferroviaria europea per un trasporto merci competitivo Testo rilevante ai fini del SEE (GU L 276 del 20.10.2010)_______ Modificato da: -… Leggi tutto
Lug 08, 2025 142

Regolamento (UE) 2021/1153

Regolamento (UE) 2021/1153 ID 24251 | 08.07.2025 Regolamento (UE) 2021/1153 del Parlamento europeo e del Consiglio del 7 luglio 2021 che istituisce il meccanismo per collegare l’Europa e abroga i regolamenti (UE) n. 1316/2013 e (UE) n. 283/2014. (GU L 249 del 14.7.2021)_______ Modificato da:… Leggi tutto
TEN T   Trans European Network   Transport
Lug 08, 2025 218

Regolamento (UE) 2024/1679

Regolamento (UE) 2024/1679 / Rete Transeuropea dei Trasporti (TEN-T / Trans-European Network - Transport ) ID 24250 | 08.07.2025 Regolamento (UE) 2024/1679 del Parlamento europeo e del Consiglio, del 13 giugno 2024, sugli orientamenti dell'Unione per lo sviluppo della rete transeuropea dei… Leggi tutto

Ultimi Documenti Abbonati

FAQ   UNI 7129 1 2015 e UNI 11528 2022   Chiarimento sistemi PLT CSST
Lug 07, 2025 264

FAQ - UNI 7129-1:2015 e UNI 11528:2022 - Chiarimento sistemi PLT-CSST

FAQ - UNI 7129-1:2015 e UNI 11528:2022 - Chiarimento sistemi PLT-CSST ID 24237 | 07.07.2025 / In allegato FAQ - UNI 7129-1:2015 e UNI 11528:2022 - Chiarimento sistemi PLT-CSST E’ stato posto al CIG un quesito riguardante la corretta interpretazione sulla regolamentazione dei sistemi PLT-CSST in… Leggi tutto
EN 415 2 2025 Packaging machines for pre formed rigid containers
Lug 03, 2025 377

EN 415-2:2025 / Packaging machines for pre-formed rigid containers

EN 415-2:2025 / Packaging machines for pre-formed rigid containers ID 24216 | 03.07.2025 / Preview attached EN 415-2:2025Safety of packaging machines - Part 2: Packaging machines for pre-formed rigid containers Valid from 01.07.2025 This document applies to the following machines and to machines… Leggi tutto
UNI 11555 2025 Posatori di sistemi a secco in lastre
Lug 03, 2025 381

UNI 11555:2025 / Posatori di sistemi a secco in lastre

UNI 11555:2025 / Posatori di sistemi a secco in lastre ID 24215 | 03.07.2025 / In allegato Preview UNI 11555:2025Attività professionali non regolamentate - Posatori di sistemi a secco in lastre - Requisiti di conoscenza, abilità, autonomia e responsabilità La norma definisce i requisiti relativi al… Leggi tutto